<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734617</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001223</org_study_id>
    <nct_id>NCT00734617</nct_id>
  </id_info>
  <brief_title>Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II</brief_title>
  <acronym>CON NIC II</acronym>
  <official_title>Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goals of the study are to assess benefits of higher doses of the nicotine patch&#xD;
      prior to smoking cessation for high- and low-dependent smokers, and to investigate the&#xD;
      potential relationship between genetic factors and smoking cessation success. There will be a&#xD;
      two-week double-blind pre-cessation exposure to nicotine patch treatment in a sample of 240&#xD;
      high-dependent &amp; 240 low-dependent smokers; half of each group will wear two 21mg nicotine&#xD;
      patches (42mg) daily, and half will wear one 21mg nicotine patch and one comparable placebo&#xD;
      patch daily, resulting in the following four conditions (120 subjects each) during the 2-week&#xD;
      pre-quit period: 1) Less Dependent/21mg nic., 2) Less Dependent/42mg nic., 3) More&#xD;
      Dependent/21mg nic., and 4) More Dependent/42mg nic. After the quit date, subjects will&#xD;
      continue with the same nicotine dosage for the 1st 4 weeks; after that the treatment will no&#xD;
      longer be double-blind as only nicotine patches will be used: all subjects will wear one&#xD;
      21-mg patch daily for 2 weeks, one 14-mg patch daily for the following 2 weeks, and one 7-mg&#xD;
      patch for the remaining 2 weeks. The four treatment groups will be distributed over 4 sites:&#xD;
      Durham, Raleigh, Charlotte, and Winston-Salem. After the screening visit, subjects will have&#xD;
      7 lab visits: at 2 weeks, 1 week, and 1 day prior to the quit-smoking date, and at 1 week, 3&#xD;
      weeks, 6 weeks and 10 weeks after the quit-smoking date.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Abstinence From Smoking at Ten Weeks Post-quit</measure>
    <time_frame>May 2009</time_frame>
    <description>Continuous abstinence from the target quit date through the end of treatment (10 weeks) was assessed based on self reports of continuous abstinence (i.e., no lapses) that were confirmed by end-expired CO levels ≤ 10 ppm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">479</enrollment>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Less Dependent Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>More Dependent Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Patch</intervention_name>
    <description>Groups 1 &amp; 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day&#xD;
Groups 2 &amp; 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day</description>
    <arm_group_label>Less Dependent Smokers</arm_group_label>
    <arm_group_label>More Dependent Smokers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be 18-65 years old, have smoked an average of at least 10 cigarettes per&#xD;
             day for three cumulative or continuous years of a brand that delivers (by Federal&#xD;
             Trade Commission rated yields) at least 0.5 mg nicotine, have an expired air carbon&#xD;
             monoxide reading of at least 10 ppm, and express a desire to quit smoking.&#xD;
             Additionally, subjects must express a willingness to switch to denicotinized&#xD;
             cigarettes. A more dependent smoker is defined as someone with an FTND score of seven&#xD;
             or greater. A less dependent smoker is defined as someone with an FTND score of less&#xD;
             than seven.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For those with a known history of hypertension, systolic &gt;140 mm Hg, diastolic &gt;100 mm&#xD;
             Hg); hypotension (systolic &lt;90 mm Hg, diastolic &lt;60 mm Hg) Participants with&#xD;
             hypertension or hypotension may, however, be allowed to participate in the study if&#xD;
             the study physician or P.A. determines that the condition is stable, controlled by&#xD;
             medication, and in no way jeopardizes the individual's safety. Subjects with no&#xD;
             previous diagnosis of hypertension may have a screening blood pressure up to 160/100.&#xD;
             Potential subjects who report coronary heart disease; heart attack; cardiac rhythm&#xD;
             disorder (irregular heart rhythm); chest pains (unless history, exam, and EKG clearly&#xD;
             indicate a non-cardiac source); cardiac (heart) disorder (including but not limited to&#xD;
             valvular heart disease, heart murmur, heart failure); history of skin allergy; active&#xD;
             skin condition (psoriasis) within the last five years; skin disorder except minor skin&#xD;
             conditions (including but not limited to facial acne, minor localized infections, and&#xD;
             superficial minor wounds.); liver or kidney disorder (except kidney stones,&#xD;
             gallstones); gastrointestinal problems or disease other than gastroesophageal reflux&#xD;
             or heartburn; ulcers; lung disorder (including but not limited to COPD, emphysema, and&#xD;
             asthma); brain abnormality (including but not limited to, stroke, brain tumor, seizure&#xD;
             disorder); history of fainting; problems giving blood samples; difficulty passing&#xD;
             urine; diabetes treated with insulin, non-insulin treated diabetes (unless glucose is&#xD;
             less than 180mg/dcl and HbA1c is less than 7%); current cancer or treatment for cancer&#xD;
             in the past 6 months(except basal or squamous cell skin cancer); other major medical&#xD;
             condition; current psychiatric disease (with the exception of depression, anxiety&#xD;
             disorders, OCD and ADHD) will be excluded from the study. Potential subjects who do&#xD;
             not have a self reported diagnosis of the above listed conditions may be excluded if&#xD;
             the study physician or P.A. determines that the history, physical findings, EKG, or&#xD;
             laboratory studies reveal information that may jeopardize the subject's safe study&#xD;
             participation.&#xD;
&#xD;
        Potential subjects who have abused alcohol or drugs, or have used within the last 30 days&#xD;
        experimental (investigational) drugs, psychiatric medications (including antidepressants,&#xD;
        anti-psychotics) or any other medications that are known to affect smoking cessation (e.g.&#xD;
        clonidine) will be excluded. Potential subjects who have used smokeless tobacco (chewing&#xD;
        tobacco, snuff), cigars, pipes, nicotine replacement therapy, or other smoking cessation&#xD;
        treatment within the last 2 weeks will be excluded. Pregnant or nursing mothers will be&#xD;
        excluded.&#xD;
&#xD;
        Use of non-opiate medications for pain or sleep will be allowed. For medical conditions&#xD;
        that do not appear above, the study physician will be consulted and if the medical&#xD;
        condition does not jeopardize safe study participation, then the subject may be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jed E Rose, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <results_first_submitted>February 3, 2011</results_first_submitted>
  <results_first_submitted_qc>February 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2011</results_first_posted>
  <last_update_submitted>July 2, 2014</last_update_submitted>
  <last_update_submitted_qc>July 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cigarette</keyword>
  <keyword>Nicotine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment start date: 8/20/2007 Recruitment end date: 3/19/2008 Recruitment locations: Duke Center for Nicotine &amp; Smoking Cessation Research offices located in Charlotte, Durham, Raleigh and Winston-Salem NC.</recruitment_details>
      <pre_assignment_details>Participants were excluded for the following reasons:&#xD;
DID NOT MEET INCLUSION CRITERIA: 78 MET EXCLUSION CRITERIA: 74 UNABLE TO MEET STUDY REQUIREMENTS: 9 REFUSED TO PARTICIPATE: 18 LOST TO CONTACT (PRIOR TO V1): 30 LAB RESULTS: 64 MD/PA REFUSAL: 179 30 DAYS PAST PHYSICAL SCREENING: 1</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Less Dependent</title>
        </group>
        <group group_id="P2">
          <title>More Dependent</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Less Dependent</title>
        </group>
        <group group_id="B2">
          <title>More Dependent</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="230"/>
            <count group_id="B3" value="479"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="11.4"/>
                    <measurement group_id="B2" value="44.34" spread="10.92"/>
                    <measurement group_id="B3" value="43.53" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Abstinence From Smoking at Ten Weeks Post-quit</title>
        <description>Continuous abstinence from the target quit date through the end of treatment (10 weeks) was assessed based on self reports of continuous abstinence (i.e., no lapses) that were confirmed by end-expired CO levels ≤ 10 ppm.</description>
        <time_frame>May 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Less Dependent</title>
          </group>
          <group group_id="O2">
            <title>More Dependent</title>
          </group>
        </group_list>
        <measure>
          <title>Continuous Abstinence From Smoking at Ten Weeks Post-quit</title>
          <description>Continuous abstinence from the target quit date through the end of treatment (10 weeks) was assessed based on self reports of continuous abstinence (i.e., no lapses) that were confirmed by end-expired CO levels ≤ 10 ppm.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>21mg Nicotine Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42mg Nicotine Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Less Dependent</title>
        </group>
        <group group_id="E2">
          <title>More Dependent</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jed E. Rose, Ph.D.</name_or_title>
      <organization>Duke Center for Nicotine &amp; Smoking Cessation Research</organization>
      <phone>919 668-5093</phone>
      <email>rose0003@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

